Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(10):1376–1381. doi: 10.1038/bjc.1997.563

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

C J Punt 1, E E Voest 1, E Tueni 1, A T Van Oosterom 1, A Backx 1, P H De Mulder 1, B Hecquet 1, C Lucas 1, B Gerard 1, H Bleiberg 1
PMCID: PMC2228136  PMID: 9374386

Abstract

S9788 is a new triazineaminopiperidine derivate capable of reversing multidrug resistance (MDR) in cells resistant to chemotherapeutic agents such as doxorubicin. It does not belong to a known class of MDR revertants, but its action involves the binding of P-glycoprotein. Thirty-eight evaluable patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone (16 patients) followed after disease progression with combination treatment of doxorubicin plus S9788 (12 patients) or upfront with the combination of doxorubicin plus S9788 (22 patients). S9788 was given i.v. as a loading dose of 56 mg m-2 over 30 min followed by doxorubicin given at 50 mg m-2 as a bolus infusion. Thereafter, a 2-h infusion of S9788 was administered at escalating doses ranging from 24 to 120 mg m-2 in subsequent cohorts of 4-10 patients. Pharmacokinetic analysis demonstrated that concentrations of S9788 that are known to reverse MDR in vitro were achieved in patients at non-toxic doses. Compared with treatment with doxorubicin alone, treatment with the combination of doxorubicin and S9788 produced a significant increase in the occurrence of WHO grade 3-4 granulocytopenia. Treatment with S9788 was cardiotoxic as it caused a dose-dependent and reversible increase in corrected QT intervals as well as clinically non-significant arrhythmias on 24- or 48-h Holter recordings. Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of S9788 may increase the risk of severe cardiac arrhythmias. Twenty-nine patients treated with S9788 plus doxorubicin were evaluable for response, and one patient, who progressed after treatment with doxorubicin alone, achieved a partial response. We conclude that S9788 administered at the doses and schedule used in this study results in relevant plasma concentrations in humans and can safely be administered in combination with doxorubicin.

Full text

PDF
1376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakes D. M., Turner N. D., Gordon B. H., Hiley M. P., Walther B., Lucas C. Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1993 May 19;615(1):117–126. doi: 10.1016/0378-4347(93)80297-h. [DOI] [PubMed] [Google Scholar]
  2. Bartlett N. L., Lum B. L., Fisher G. A., Brophy N. A., Ehsan M. N., Halsey J., Sikic B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994 Apr;12(4):835–842. doi: 10.1200/JCO.1994.12.4.835. [DOI] [PubMed] [Google Scholar]
  3. Bender K. S., Shematek J. P., Leventhal B. G., Kan J. S. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr. 1984 Sep;105(3):442–444. doi: 10.1016/s0022-3476(84)80026-8. [DOI] [PubMed] [Google Scholar]
  4. Chapman A. E., Goldstein L. J. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol. 1995 Feb;22(1):17–28. [PubMed] [Google Scholar]
  5. Cros S., Guilbaud N., Berlion M., Dunn T., Regnier G., Dhainaut A., Atassi G., Bizzari J. P. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol. 1992;30(6):491–494. doi: 10.1007/BF00685604. [DOI] [PubMed] [Google Scholar]
  6. Efferth T., Dunn T. A., Berlion M., Langenbahn H., Pommerenke E. W., Volm M. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788. Anticancer Res. 1993 Jul-Aug;13(4):905–908. [PubMed] [Google Scholar]
  7. Frytak S., Moertel C. G., Schutt A. J., Hahn R. G., Reitemeier R. J. Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer. Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):405–409. [PubMed] [Google Scholar]
  8. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  9. Hill B. T., van der Graaf W. T., Hosking L. K., de Vries E. G., Mulder N. H., Whelan R. D. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro. Int J Cancer. 1993 Sep 9;55(2):330–337. doi: 10.1002/ijc.2910550225. [DOI] [PubMed] [Google Scholar]
  10. Huet S., Chapey C., Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer. 1993;29A(10):1377–1383. doi: 10.1016/0959-8049(93)90005-z. [DOI] [PubMed] [Google Scholar]
  11. Julia A. M., Roché H., Berlion M., Lucas C., Milano G., Robert J., Bizzari J. P., Canal P. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil. Br J Cancer. 1994 May;69(5):868–874. doi: 10.1038/bjc.1994.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kanamaru H., Kakehi Y., Yoshida O., Nakanishi S., Pastan I., Gottesman M. M. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst. 1989 Jun 7;81(11):844–849. doi: 10.1093/jnci/81.11.844. [DOI] [PubMed] [Google Scholar]
  13. Kramer R., Weber T. K., Morse B., Arceci R., Staniunas R., Steele G., Jr, Summerhayes I. C. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer. 1993 May;67(5):959–968. doi: 10.1038/bjc.1993.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lai G. M., Chen Y. N., Mickley L. A., Fojo A. T., Bates S. E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991 Nov 11;49(5):696–703. doi: 10.1002/ijc.2910490512. [DOI] [PubMed] [Google Scholar]
  15. Léonce S., Pierré A., Anstett M., Pérez V., Genton A., Bizzari J. P., Atassi G. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol. 1992 Nov 3;44(9):1707–1715. doi: 10.1016/0006-2952(92)90063-o. [DOI] [PubMed] [Google Scholar]
  16. Merlin J. L., Guerci A., Marchal S., Missoum N., Ramacci C., Humbert J. C., Tsuruo T., Guerci O. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood. 1994 Jul 1;84(1):262–269. [PubMed] [Google Scholar]
  17. Pennock G. D., Dalton W. S., Roeske W. R., Appleton C. P., Mosley K., Plezia P., Miller T. P., Salmon S. E. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst. 1991 Jan 16;83(2):105–110. doi: 10.1093/jnci/83.2.105. [DOI] [PubMed] [Google Scholar]
  18. Pierré A., Dunn T. A., Kraus-Berthier L., Léonce S., Saint-Dizier D., Régnier G., Dhainaut A., Berlion M., Bizzari J. P., Atassi G. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest New Drugs. 1992 Aug;10(3):137–148. doi: 10.1007/BF00877238. [DOI] [PubMed] [Google Scholar]
  19. Pérez V., Pierré A., Léonce S., Anstett M., Atassi G. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin. Anticancer Res. 1993 Jul-Aug;13(4):985–990. [PubMed] [Google Scholar]
  20. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer. 1993 Dec 15;72(12):3553–3563. doi: 10.1002/1097-0142(19931215)72:12<3553::aid-cncr2820721203>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  21. Redmond S. M., Joncourt F., Buser K., Ziemiecki A., Altermatt H. J., Fey M., Margison G., Cerny T. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 1991 Apr 15;51(8):2092–2097. [PubMed] [Google Scholar]
  22. Roninson I. B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol. 1992 Jan 9;43(1):95–102. doi: 10.1016/0006-2952(92)90666-7. [DOI] [PubMed] [Google Scholar]
  23. Scheithauer W., Schenk T., Czejka M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer. 1993 Jul;68(1):8–9. doi: 10.1038/bjc.1993.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schwartz C. L., Hobbie W. L., Truesdell S., Constine L. C., Clark E. B. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993 Oct;11(10):1906–1910. doi: 10.1200/JCO.1993.11.10.1906. [DOI] [PubMed] [Google Scholar]
  25. Sebille S., Morjani H., Poullain M. G., Manfait M. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry. Anticancer Res. 1994 Nov-Dec;14(6A):2389–2393. [PubMed] [Google Scholar]
  26. Soudon J., Berlion M., Lucas C., Haddad P., Bizzari J. P., Calvo F. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol. 1995;36(3):195–203. doi: 10.1007/BF00685846. [DOI] [PubMed] [Google Scholar]
  27. Stinson J. C., Pears J. S., Williams A. J., Campbell R. W. Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol. 1995 Jun;39(6):651–656. doi: 10.1111/j.1365-2125.1995.tb05724.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Surawicz B., Knoebel S. B. Long QT: good, bad or indifferent? J Am Coll Cardiol. 1984 Aug;4(2):398–413. doi: 10.1016/s0735-1097(84)80232-6. [DOI] [PubMed] [Google Scholar]
  29. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol. 1995 Feb;22(1):42–60. [PubMed] [Google Scholar]
  30. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES